MetLife Investment Management LLC Purchases New Position in Tempus AI, Inc. $TEM

MetLife Investment Management LLC purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,658 shares of the company’s stock, valued at approximately $225,000.

Other large investors also recently bought and sold shares of the company. Cherry Tree Wealth Management LLC bought a new position in Tempus AI in the first quarter worth approximately $31,000. University of Texas Texas AM Investment Management Co. bought a new position in Tempus AI in the first quarter worth approximately $33,000. Continuum Advisory LLC bought a new position in Tempus AI in the first quarter worth approximately $39,000. Bartlett & CO. Wealth Management LLC raised its stake in Tempus AI by 100.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company’s stock worth $39,000 after buying an additional 400 shares in the last quarter. Finally, Nemes Rush Group LLC bought a new position in Tempus AI in the first quarter worth approximately $39,000. Institutional investors own 24.22% of the company’s stock.

Insider Activity

In other Tempus AI news, CAO Ryan M. Bartolucci sold 1,904 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $142,133.60. Following the completion of the sale, the chief accounting officer directly owned 45,895 shares in the company, valued at approximately $3,426,061.75. The trade was a 3.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Erik Phelps sold 3,664 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $273,517.60. Following the completion of the sale, the executive vice president directly owned 94,115 shares in the company, valued at approximately $7,025,684.75. The trade was a 3.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 903,104 shares of company stock valued at $63,733,330. 26.27% of the stock is owned by corporate insiders.

Tempus AI Price Performance

Shares of TEM opened at $81.01 on Wednesday. The firm has a market capitalization of $14.07 billion, a PE ratio of -68.08 and a beta of 5.08. The company has a debt-to-equity ratio of 2.58, a current ratio of 1.54 and a quick ratio of 1.43. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $91.45. The company’s fifty day moving average price is $66.15 and its 200-day moving average price is $59.16.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The firm had revenue of $314.64 million for the quarter, compared to analyst estimates of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The business’s quarterly revenue was up 89.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TEM. Needham & Company LLC reissued a “buy” rating and issued a $70.00 price objective on shares of Tempus AI in a research note on Friday, August 8th. BTIG Research lifted their price objective on shares of Tempus AI from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, August 20th. Bank of America lifted their price objective on shares of Tempus AI from $68.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 25th. Morgan Stanley lifted their price objective on shares of Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 12th. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Tempus AI in a research report on Friday, August 8th. Seven research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $69.50.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.